(Q46393065)

English

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

phase III clinical trial

0 references

author name string

Jacques P Brown

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Richard L Prince

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Chad Deal

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Robert R Recker

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Douglas P Kiel

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Luiz H de Gregorio

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Peyman Hadji

7

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Lorenz C Hofbauer

8

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Jose M Alvaro-Gracia

9

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Huei Wang

10

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Matthew Austin

11

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Rachel B Wagman

12

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Richard Newmark

13

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Cesar Libanati

14

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Javier San Martin

15

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Henry G Bone

16

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

publication date

1 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Journal of Bone and Mineral Research

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

24

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

153-161

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

Osteoporosis prevention, diagnosis, and therapy

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

National trends in osteoporosis visits and osteoporosis treatment, 1988-2003.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Effects of risedronate on fracture risk in postmenopausal women with osteopenia

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Risedronate prevents new vertebral fractures in postmenopausal women at high risk

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Denosumab in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

A sharper Bonferroni procedure for multiple tests of significance

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study

1 reference

https://api.crossref.org/works/10.1359%2FJBMR.0809010

21 January 2018

Identifiers

10.1359/JBMR.0809010

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18767928

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46393065&oldid=2109231544"